As the U.S. stock market experiences a positive streak, with the Dow Jones and S&P 500 extending their gains amidst strong earnings reports and potential tariff adjustments, investors are closely ...

Halozyme Therapeutics (HALO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.